Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA, Industry Agree On Working Groups To Support User-Fee Negotiations

This article was originally published in The Gray Sheet

Executive Summary

The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.


Related Content

User-Fee Sticker Shock? Industry Pursues Trimmed-Down MDUFA IV Proposal
Industry, FDA Outline Costs Of New MDUFA Proposals; Quality Management A Strong Focus
Commissioner Califf: Cardiologist, Clinical Trials Expert Ascends At FDA
Next AdvaMed Chief Is BIO Exec Scott Whitaker
FDA Counter-Offers On Industry CLIA Waiver Proposal
New Fundings And Goals To Match Raised In Latest MDUFA IV Session
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA Tries To Get 'Smart' In Standardizing 510(k) Reviews
Industry Challenges FDA's User Fee Markup
TurboTax For 510(k)s? FDA Seeks Volunteers For eSubmissions Pilot





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts